Madrigal Pharmaceuticals, Inc. MDGL Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s operating cash flow?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported operating cash flow of -$167.44M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s operating cash flow decreased by 88.4% year-over-year, from -$88.89M to -$167.44M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s operating cash flow?
- Over 3 years (2021 to 2024), Madrigal Pharmaceuticals, Inc.'s operating cash flow has grown at a 35.3% compound annual growth rate (CAGR), from -$183.92M to -$455.57M.
- What does operating cash flow mean?
- The net cash result of running the company's core business operations.
- How do you interpret operating cash flow?
- Higher values indicate strong operational cash generation, while negative values signal cash burn, common in clinical-stage biopharma.
- How does operating cash flow compare across companies?
- Critical for evaluating the sustainability of clinical-stage companies before commercial revenue scales.